# Merit E Cudkowicz

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 117 papers | 9,091 citations | 66343 42 h-index | 45317 90 g-index |
| 124 all docs | 124 docs citations | 124 times ranked | 10338 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Gait variability and basal ganglia disorders: Strideâ€toâ€stride variations of gait cycle timing in parkinson's disease and Huntington's disease. Movement Disorders, 1998, 13, 428-437. | 3.9 | 752 |
| 2 | Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-Derived Motor Neurons. Cell Reports, 2014, 7, 1-11. | 6.4 | 583 |
| 3 | Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6. | 8.1 | 517 |
| 4 | Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis. Journal of Applied Physiology, 2000, 88, 2045-2053. | 2.5 | 400 |
| 5 | Phase 1â€“2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 2020, 383, 109-119. | 27.0 | 354 |
| 6 | Trial of Sodium Phenylbutyrateâ€“Taursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine, 2020, 383, 919-930. | 27.0 | 299 |
| 7 | Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron, 2014, 83, 1043-1050. | 8.1 | 289 |
| 8 | Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology, 2006, 60, 22-31. | 5.3 | 276 |
| 9 | Natural history of infantileâ€onset spinal muscular atrophy. Annals of Neurology, 2017, 82, 883-891. | 5.3 | 276 |
| 10 | Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet, The, 2014, 383, 2065-2072. | 13.7 | 233 |
| 11 | The PRO-ACT database. Neurology, 2014, 83, 1719-1725. | 1.1 | 222 |
| 12 | Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurology, The, 2013, 12, 1059-1067. | 10.2 | 216 |
| 13 | Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease. JAMA Neurology, 2014, 71, 141. | 9.0 | 211 |
| 14 | Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2014, 13, 1083-1091. | 10.2 | 187 |
| 15 | Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nature Biotechnology, 2015, 33, 51-57. | 17.5 | 178 |
| 16 | Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28. NeuroImage: Clinical, 2015, 7, 409-414. | 2.7 | 176 |
| 17 | Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. Journal of Clinical Investigation, 2018, 128, 3558-3567. | 8.2 | 171 |
| 18 | The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nature Medicine, 2011, 17, 1652-1656. | 30.7 | 166 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118. | 10.1 | 152 |
| 20 | Phase 2 study of sodium phenylbutyrate in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 99-106. | 2.1 | 135 |
| 21 | Transplantation of spinal cordâ€“derived neural stem cells for ALS. Neurology, 2016, 87, 392-400. | 1.1 | 127 |
| 22 | Expanded autologous regulatory T-lymphocyte infusions in ALS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e465. | 6.0 | 116 |
| 23 | Longâ€term survival of participants in the <scp>CENTAUR</scp> trial of sodium phenylbutyrateâ€taurursodiol in <scp>amyotrophic lateral sclerosis</scp>. Muscle and Nerve, 2021, 63, 31-39. | 2.2 | 115 |
| 24 | Final Results of the RHAPSODY Trial: A Multiâ€Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3Aâ€APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Annals of Neurology, 2019, 85, 125-136. | 5.3 | 113 |
| 25 | Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle and Nerve, 2008, 38, 837-844. | 2.2 | 104 |
| 26 | Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology, 2018, 90, e565-e574. | 1.1 | 99 |
| 27 | NurOwn, phase 2, randomized, clinical trial in patients with ALS. Neurology, 2019, 93, e2294-e2305. | 1.1 | 95 |
| 28 | The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 162-168. | 1.7 | 88 |
| 29 | Randomized phase 2 trial of NP001, a novel immune regulator. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e100. | 6.0 | 83 |
| 30 | Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology, 2016, 87, 2554-2561. | 1.1 | 83 |
| 31 | A futility study of minocycline in Huntington's disease. Movement Disorders, 2010, 25, 2219-2224. | 3.9 | 79 |
| 32 | Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186. | 9.0 | 79 |
| 33 | How common are ALS plateaus and reversals?. Neurology, 2016, 86, 808-812. | 1.1 | 78 |
| 34 | Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 259-265. | 2.1 | 77 |
| 35 | Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Neurotherapeutics, 2017, 14, 762-772. | 4.4 | 73 |
| 36 | A randomized trial of mexiletine in ALS. Neurology, 2016, 86, 1474-1481. | 1.1 | 72 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Defining SOD1 ALS natural history to guide therapeutic clinical trial design. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 99-105. | 1.9 | 68 |
| 38 | Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nature Neuroscience, 2022, 25, 226-237. | 14.8 | 66 |
| 39 | Measures and markers in Amyotrophic Lateral Sclerosis. NeuroRx, 2004, 1, 273-283. | 6.0 | 63 |
| 40 | Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle and Nerve, 2020, 62, 156-166. | 2.2 | 60 |
| 41 | Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology, 2022, 98, . | 1.1 | 51 |
| 42 | Outcome measures in amyotrophic lateral sclerosis clinical trials. Clinical Investigation, 2014, 4, 605-618. | 0.0 | 50 |
| 43 | Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach. Scientific Reports, 2019, 9, 690. | 3.3 | 46 |
| 44 | Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial. PLoS ONE, 2014, 9, e97803. | 2.5 | 45 |
| 45 | Respiratory measures in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 321-330. | 1.7 | 44 |
| 46 | A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 250-258. | 1.7 | 44 |
| 47 | Amyotrophic lateral sclerosis care and research in the United States during the <scp>COVID</scp>â€19 pandemic: Challenges and opportunities. Muscle and Nerve, 2020, 62, 182-186. | 2.2 | 42 |
| 48 | A randomized <scp>placeboâ€controlled</scp> phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle and Nerve, 2022, 65, 291-302. | 2.2 | 41 |
| 49 | Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. Annals of Neurology, 2022, 91, 165-175. | 5.3 | 41 |
| 50 | Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Openâ€Access ALS clinical trials database. Muscle and Nerve, 2018, 57, 430-434. | 2.2 | 39 |
| 51 | Developing multidisciplinary clinics for neuromuscular care and research. Muscle and Nerve, 2017, 56, 848-858. | 2.2 | 38 |
| 52 | Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, doubleâ€blind crossover trial. Muscle and Nerve, 2018, 58, 42-48. | 2.2 | 38 |
| 53 | Quantitative strength testing in ALS clinical trials. Neurology, 2016, 87, 617-624. | 1.1 | 37 |
| 54 | Race/ethnicity, socioeconomic status, and ALS mortality in the United States. Neurology, 2016, 87, 2300-2308. | 1.1 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 871-875. | 1.9 | 37 |
| 56 | An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 242-249. | 1.7 | 35 |
| 57 | Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics â€“ An AI-Enabled Biological Target Discovery Platform. Frontiers in Aging Neuroscience, 0, 14, . | 3.4 | 32 |
| 58 | Understanding the use of NIV in ALS: results of an international ALS specialist survey. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 331-341. | 1.7 | 31 |
| 59 | Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1522-1533. | 3.7 | 31 |
| 60 | Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discovery Today, 2015, 20, 65-75. | 6.4 | 30 |
| 61 | Job-related formaldehyde exposure and ALS mortality in the USA: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 786-788. | 1.9 | 30 |
| 62 | Survival analyses from the <scp>CENTAUR</scp> trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes. Muscle and Nerve, 2022, 66, 136-141. | 2.2 | 30 |
| 63 | Imaging of glia activation in people with primary lateral sclerosis. NeuroImage: Clinical, 2018, 17, 347-353. | 2.7 | 29 |
| 64 | Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology, 2019, 93, e1605-e1617. | 1.1 | 29 |
| 65 | A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 584-594. | 1.7 | 29 |
| 66 | A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle and Nerve, 2019, 59, 303-308. | 2.2 | 29 |
| 67 | Tocilizumab is safe and tolerable and reduces <scp>C</scp>â€reactive protein concentrations in the plasma and cerebrospinal fluid of <scp>ALS</scp> patients. Muscle and Nerve, 2021, 64, 309-320. | 2.2 | 27 |
| 68 | Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss. Science Translational Medicine, 2021, 13, . | 12.4 | 27 |
| 69 | Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. Scientific Reports, 2019, 9, 17728. | 3.3 | 26 |
| 70 | Preâ€morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle and Nerve, 2015, 52, 339-343. | 2.2 | 25 |
| 71 | Vitamin D levels are associated with gross motor function in amyotrophic lateral sclerosis. Muscle and Nerve, 2017, 56, 726-731. | 2.2 | 22 |
| 72 | Risk factors for suicidality in Huntington disease. Neurology, 2019, 92, e1643-e1651. | 1.1 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 259-266. | 1.7 | 21 |
| 74 | Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. NeuroImage: Clinical, 2021, 30, 102672. | 2.7 | 21 |
| 75 | Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection. Stroke, 2016, 47, 2979-2985. | 2.0 | 20 |
| 76 | Serum urate at trial entry and ALS progression in EMPOWER. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 120-125. | 1.7 | 20 |
| 77 | A Phase 1 study of <scp>GDC</scp>â€0134, a dual leucine zipper kinase inhibitor, in <scp>ALS</scp>. Annals of Clinical and Translational Neurology, 2022, 9, 50-66. | 3.7 | 20 |
| 78 | Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2022, 59, 683-702. | 4.0 | 18 |
| 79 | Locked in, but not out?. Neurology, 2014, 82, 1852-1853. | 1.1 | 17 |
| 80 | Primary Lateral Sclerosis and Early Upper Motor Neuron Disease. Journal of Clinical Neuromuscular Disease, 2016, 17, 99-105. | 0.7 | 17 |
| 81 | Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). Journal of Neurology & Neurophysiology, 2017, 08, . | 0.1 | 17 |
| 82 | Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. EBioMedicine, 2018, 33, 169-184. | 6.1 | 17 |
| 83 | Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. Frontiers in Neurology, 2020, 11, 590573. | 2.4 | 16 |
| 84 | Gold Coast diagnostic criteria: Implications for <scp>ALS</scp> diagnosis and clinical trial enrollment. Muscle and Nerve, 2021, 64, 532-537. | 2.2 | 16 |
| 85 | Phase <scp>2B</scp> randomized controlled trial of <scp>NP001</scp> in amyotrophic lateral sclerosis: Preâ€specified and post hoc analyses. Muscle and Nerve, 2022, 66, 39-49. | 2.2 | 16 |
| 86 | Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. Muscle and Nerve, 2017, 56, 710-715. | 2.2 | 15 |
| 87 | Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntingtonâ€™s Disease Patientsâ€”A Randomized Phase 2 Clinical Trial. Journal of Clinical Medicine, 2020, 9, 3682. | 2.4 | 15 |
| 88 | Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis postâ€mortem motor cortex and cerebrospinal fluid. Brain Pathology, 2022, 32, e13035. | 4.1 | 15 |
| 89 | Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. BMC Neurology, 2019, 19, 104. | 1.8 | 13 |
| 90 | Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle and Nerve, 2021, 63, 371-383. | 2.2 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 15-23. | 1.7 | 12 |
| 92 | Maximum voluntary isometric contraction (MVIC). Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 84-85. | 1.2 | 11 |
| 93 | Cortical Hyperexcitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2015, 72, 1235. | 9.0 | 11 |
| 94 | Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!. Contemporary Clinical Trials Communications, 2018, 11, 113-119. | 1.1 | 11 |
| 95 | An expanded access protocol of <scp>RT001</scp> in amyotrophic lateral sclerosisâ€"Initial experience with a lipid peroxidation inhibitor. Muscle and Nerve, 2022, 66, 421-425. | 2.2 | 10 |
| 96 | Regional prefrontal cortical atrophy predicts specific cognitive-behavioral symptoms in ALS-FTD. Brain Imaging and Behavior, 2021, 15, 2540-2551. | 2.1 | 9 |
| 97 | Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq1 1 0.784314 rgBT /Overlo 821-831. | 10.2 | 9 |
| 98 | Preclinical rodent toxicity studies for long term use of ceftriaxone. Toxicology Reports, 2015, 2, 1396-1403. | 3.3 | 7 |
| 99 | Opinion and Special Articles: Challenges and opportunities in defining career identity in academic neurology. Neurology, 2018, 91, 670-672. | 1.1 | 6 |
| 100 | Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€"Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology, 2020, 77, 755. | 9.0 | 6 |
| 101 | Preface: promoting research in PLS: current knowledge and future challenges. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 1-2. | 1.7 | 6 |
| 102 | ALSUntangled #64: butyrates. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 638-643. | 1.7 | 6 |
| 103 | The Role of Environmental Toxins in Amyotrophic Lateral Sclerosis Risk. JAMA Neurology, 2016, 73, 779. | 9.0 | 5 |
| 104 | ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 216-221. | 1.7 | 5 |
| 105 | Regulatory Approval in ALS; When Is a Single Study Enough?. Annals of Neurology, 2022, 91, 737-739. | 5.3 | 4 |
| 106 | ALSUntangled #63: ketogenic diets. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 159-163. | 1.7 | 3 |
| 107 | Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. Journal of Neurochemistry, 2006, 96, 908-908. | 3.9 | 2 |
| 108 | Reply. Muscle and Nerve, 2015, 52, 691-691. | 2.2 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | ALS/SURV: a modification of the CAFS statistic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 576-583. | 1.7 | 2 |
| 110 | ISDN2014_0028: REMOVED: Targeting miRâ€155 restores dysfunctional microglia and ameliorates disease in the SOD1 model of ALS. International Journal of Developmental Neuroscience, 2015, 47, 5-5. | 1.6 | 1 |
| 111 | Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstacles. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 66-75. | 1.7 | 1 |
| 112 | Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-Oncology Advances, 2022, 4, vdab186. | 0.7 | 1 |
| 113 | Analysis of Participant Withdrawal in Huntington Disease Clinical Trials. Journal of Huntington's Disease, 2017, 6, 149-156. | 1.9 | 0 |
| 114 | Baseline Variables Associated with Functional Decline in 2CARE, A Randomized Clinical Trial in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2020, 9, 47-58. | 1.9 | 0 |
| 115 | Noninvasive ventilation use by patients enrolled in VITALITY-ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 1-9. | 1.7 | 0 |
| 116 | Measures and markers in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2004, 1, 273-283. | 4.4 | 0 |
| 117 | Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design. Neurology: Clinical Practice, 2021, 11, e472-e479. | 1.6 | 0 |